Status:
COMPLETED
Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma
Lead Sponsor:
University of Cologne
Conditions:
Hodgkin´s Lymphoma
Eligibility:
All Genders
61-75 years
Phase:
PHASE2
Brief Summary
This study is designed to test (1) feasibility and efficiancy of new BACOPP regimen and (2) toxicity, overall response and FFTF.
Eligibility Criteria
Inclusion
- Hodgkin´s lymphoma (histologically proven)
- CS (PS) I and II with one of the risk factors a-d
- bulky mediastinal mass (\> 1/3 maximum transverse thorax diameter)
- extranodal involvement
- ESR \> 50 (A), \> 30 (B-symptoms)
- 3 or more lymph node areas involved
- CS (PS) III and IV
- Written informed consent
Exclusion
- Leukocytes \<3000/microl
- Platelets \<100000/microl
- Hodgkin´s Disease as "composite lymphoma"
- Activity index (WHO) \< grade 2
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT00284271
Start Date
January 1 2004
Last Update
July 29 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Cologne
Cologne, Germany, 50931